최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.29 no.4, 2019년, pp.254 - 266
김청수 (아주대학교 대학원 의생명과학과) , 이지민 (아주대학교 약학대학) , 박래웅 (아주대학교 대학원 의생명과학과) , 이숙향 (아주대학교 약학대학)
Background: Patients with cardiovascular risks are recommended to use statins and antiplatelet agents to prevent major cerebro-cardiovascular events (MACCE). Antiplatelet agents also possess anti-inflammatory and antioxidant effects, in addition to their inhibitory activity on platelets. The differe...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
Statin이란? | 항고지질혈증 약제인 Statin과 항혈소판제를 병용하는 허혈성 심장질환 환자에게서 항혈소판제 clopidogrel, cilostazol, sarpogrelate의 종류에 따른 임상적 주요 심뇌혈관 사건 발생의 차이가 없었으며, 허혈성 심장질환 환자에서 aspirin, clopidogrel 등의 약물 사용이 제한적일 때 심혈관질환의 예방요법으로 cilostazol, sarpogrelate의 사용 가능성을 제안해 볼 수 있다. | |
Cilostazol의 효과는? | Cilostazol은 신장 세포보호 효과나 항염증 효과가 동물 실험이나 후향적 연구에서 보고되었으며, 당뇨병 환자에서 신기능의 저하가 나타날 때 단백뇨와 신기능 저하 진행의 예방에 있어서 연관성도 보고되었다.22-25) 또한 동물 실험에서 Pravastatincilostazol 병용 투여가 죽상경화증 예방에 효과가 있다는 것을 보여주었으며,26) statin과 sarpogrelate 병용 투여도 심장질환 및 신장보호에 상승효과를 보여주었다. | |
Cilostazol과 다른 약물을 병용했을 때의 효과는? | Cilostazol은 신장 세포보호 효과나 항염증 효과가 동물 실험이나 후향적 연구에서 보고되었으며, 당뇨병 환자에서 신기능의 저하가 나타날 때 단백뇨와 신기능 저하 진행의 예방에 있어서 연관성도 보고되었다.22-25) 또한 동물 실험에서 Pravastatincilostazol 병용 투여가 죽상경화증 예방에 효과가 있다는 것을 보여주었으며,26) statin과 sarpogrelate 병용 투여도 심장질환 및 신장보호에 상승효과를 보여주었다.27-29) 아시아 지역의 환자를 대상으로 진행된 임상시험에서 clopidogrel과 비교하여 cilostazol이 대안적으로 사용될 수 있다는 임상적 근거 또한 제시되었다. |
Health Insurance Review Assessment Service. Healthcare Bigdata hub. Available from http://opendata.hira.or.kr/op/opc/olapHifrqSickInfo.do. Accessed August 12, 2019.
Grundy SM and Stone NJ. 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the management of blood cholesterol: primary prevention. JAMA Cardiol 2019; 4(5):488-9.
Grundy SM and Stone NJ. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the management of blood cholesterol-secondary prevention. JAMA Cardiol 2019; 4(6):589-91.
Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e89S-e119S.
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082-115.
Johansen ME, Hefner JL, Foraker RE. Antiplatelet and statin use in US patients With coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. Am J Cardiol 2015;115:1507-12.
Ye K, Kim JT, Lee S. Effect of triple compared to dual antiplatelet therapy after drug-eluting stent implantation in percutaneous coronary intervention 2012;22:113-22.
Noh Y, Lee J, Shin S, et al. Antiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: a retrospective cohort study using the Korean national health insurance claim database. PLoS One 2016;11:e0150475.
Nakao T, Kimura T, Morimoto T, et al. The long-term efficacy of cilostazol in addition to dual antiplatelet therapy after sirolimuseluting stent implantation for Japanese patients: an analysis of the 3-year follow-up outcomes from the j-Cypher registry. Cardiovasc Interv Ther 2012;27:161-7.
Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 2009;134:351-5.
Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007;71:1867-72.
Aoki C, Hattori Y, Tomizawa A, Jojima T, Kasai K. Antiinflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo. J Atheroscler Thromb 2010;17:503-9.
Aoki M, Morishita R, Hayashi S, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001;44:1034-42.
Ogawa S, Mori T, Nako K, Ishizuka T, Ito S. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clin J Am Soc Nephrol 2008;3:362-8.
Jeong IS, Park JH, Jin SA, et al. Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers. Heart Vessels 2013;28:578-82.
Hidaka S, Kobayashi S, Iwagami M, et al. Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Ren Fail 2013;35:43-8.
Murphy B and Fraeman KH. A general SAS(R) macro to implement optimal N: 1 propensity score matching within a maximum radius 2017:13.
Fraeman K. An introduction to implementing propensity score matching with $SAS^{(R)}$ 2010. Available from https://www.researchgate.net/publication/306159704_An_introduction_to_implementing _propensity_score_matching_with_SAS. Accessed August 12, 2019.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019 Aug 31. pii: ehz425. doi: 10.1093/eurheartj/ehz425. [Epub ahead of print].
Kim IS, Jeong YH, Park Y, et al. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Br J Clin Pharmacol 2012;73:629-40.
Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9.
Hafez HM, Ibrahim MA, Zedan MZ, Hassan M, Hassanein H. Nephroprotective effect of cilostazol and verapamil against thioacetamide-induced toxicity in rats may involve Nrf2/HO-1/ NQO-1 signaling pathway. Toxicol Mech Methods 2019;29:146-52.
Noh Y, Lee J, Shin S, et al. Effects of cilostazol and reninangiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study. Int J Clin Pharm 2018;40:160-8.
Park JH, Choi BH, Ku SK, et al. Amelioration of high fat dietinduced nephropathy by cilostazol and rosuvastatin. Arch Pharm Res 2017;40:391-402.
Tang WH, Lin FH, Lee CH, et al. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine 2014;45:293-301.
Park, K-Y, Heo, T-H. Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice. Cardiovasc Ther. 2018;36:e12476.
Kim SR, Choi KH, Song YB, et al. Effect of sarpogrelate and highdose statin on the reduction of coronary spasm in vasospastic angina: A two by two factorial, pilot randomized study. Clin Cardiol 2019:10.1002/clc.23239. [Epub ahead of print.]
Yoo H, Park I, Kim DJ, Lee S. Effects of sarpogrelate on microvascular complications with type 2 diabetes. Int J Clin Pharm 2019;41:563-73.
Nomura S, Taniura T, Shouzu A, et al. Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliteransrelated biomarkers in patients with type 2 diabetes (SAREPITASO study). Vasc Health Risk Manag 2018;14:225-32.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.